Is PHAT or URGN more profitable?

Urogen Pharma has a net margin of -26.27% compared to Phathom Pharmaceuticals' net margin of -30.19%. Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals -30.19% N/A -13.38% Urogen Pharma -26.27% N/A -26.88%

Phathom Pharmaceuticals (PHAT) Competitors

$6.06 -0.17 (-2.73%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$6.08 +0.02 (+0.25%)

As of 11/13/2026 07:30 PM Eastern

Compare

PHAT vs. XERS, TRVI, MLYS, URGN, and ANIP

Should you buy Phathom Pharmaceuticals stock or one of its competitors? Phathom Pharmaceuticals's main competitors and comparable companies include Xeris Biopharma (XERS), Trevi Therapeutics (TRVI), Mineralys Therapeutics (MLYS), Urogen Pharma (URGN), and ANI Pharmaceuticals (ANIP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Phathom Pharmaceuticals compare to Xeris Biopharma?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Xeris Biopharma (NASDAQ:XERS) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Comparatively, 4.4% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Xeris Biopharma had 23 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 24 mentions for Xeris Biopharma and 1 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.82 beat Xeris Biopharma's score of 0.51 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Phathom Pharmaceuticals	Very Positive
Xeris Biopharma	Positive

Phathom Pharmaceuticals has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Xeris Biopharma has a net margin of -1.76% compared to Phathom Pharmaceuticals' net margin of -30.19%. Xeris Biopharma's return on equity of 147.75% beat Phathom Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-30.19%	N/A	-13.38%
Xeris Biopharma	-1.76%	147.75%	6.03%

Phathom Pharmaceuticals presently has a consensus target price of $20.11, suggesting a potential upside of 231.87%. Xeris Biopharma has a consensus target price of $17.00, suggesting a potential upside of 2.04%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Phathom Pharmaceuticals is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Xeris Biopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Xeris Biopharma has higher revenue and earnings than Phathom Pharmaceuticals. Xeris Biopharma is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	2.81	-$221.25M	-$1.03	N/A
Xeris Biopharma	$291.85M	10.43	$550K	-$0.05	N/A

Summary

Phathom Pharmaceuticals beats Xeris Biopharma on 9 of the 17 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 15.4% of Trevi Therapeutics shares are held by insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Trevi Therapeutics had 23 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 24 mentions for Trevi Therapeutics and 1 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.82 beat Trevi Therapeutics' score of 0.19 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Trevi Therapeutics	Neutral
Phathom Pharmaceuticals	Very Positive

Trevi Therapeutics has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

Trevi Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -30.19%. Phathom Pharmaceuticals' return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.81%	-23.96%
Phathom Pharmaceuticals	-30.19%	N/A	-13.38%

Trevi Therapeutics presently has a consensus price target of $27.08, suggesting a potential upside of 98.41%. Phathom Pharmaceuticals has a consensus price target of $20.11, suggesting a potential upside of 231.87%. Given Phathom Pharmaceuticals' higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Phathom Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Trevi Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.39	N/A
Phathom Pharmaceuticals	$175.11M	2.81	-$221.25M	-$1.03	N/A

Summary

Trevi Therapeutics beats Phathom Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Mineralys Therapeutics?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Mineralys Therapeutics has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	2.81	-$221.25M	-$1.03	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.36	N/A

Phathom Pharmaceuticals currently has a consensus target price of $20.11, suggesting a potential upside of 231.87%. Mineralys Therapeutics has a consensus target price of $43.60, suggesting a potential upside of 184.41%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Phathom Pharmaceuticals is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Mineralys Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, Mineralys Therapeutics had 8 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 9 mentions for Mineralys Therapeutics and 1 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.82 beat Mineralys Therapeutics' score of 0.13 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Phathom Pharmaceuticals	Very Positive
Mineralys Therapeutics	Neutral

Phathom Pharmaceuticals has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Mineralys Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -30.19%. Phathom Pharmaceuticals' return on equity of 0.00% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-30.19%	N/A	-13.38%
Mineralys Therapeutics	N/A	-63.26%	-56.64%

Summary

Phathom Pharmaceuticals beats Mineralys Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Urogen Pharma?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Urogen Pharma (NASDAQ:URGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Phathom Pharmaceuticals presently has a consensus target price of $20.11, indicating a potential upside of 231.87%. Urogen Pharma has a consensus target price of $53.38, indicating a potential upside of 103.88%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Phathom Pharmaceuticals is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Phathom Pharmaceuticals has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Comparatively, 4.8% of Urogen Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Urogen Pharma had 2 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 3 mentions for Urogen Pharma and 1 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.82 beat Urogen Pharma's score of 0.51 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Phathom Pharmaceuticals	Very Positive
Urogen Pharma	Positive

Urogen Pharma has a net margin of -26.27% compared to Phathom Pharmaceuticals' net margin of -30.19%.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-30.19%	N/A	-13.38%
Urogen Pharma	-26.27%	N/A	-26.88%

Urogen Pharma has higher revenue and earnings than Phathom Pharmaceuticals. Urogen Pharma is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	2.81	-$221.25M	-$1.03	N/A
Urogen Pharma	$250.25M	5.13	-$153.49M	-$1.32	N/A

Summary

Phathom Pharmaceuticals beats Urogen Pharma on 9 of the 15 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to ANI Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

ANI Pharmaceuticals has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	1.84	$78.34M	$5.02	14.23
Phathom Pharmaceuticals	$175.11M	2.81	-$221.25M	-$1.03	N/A

In the previous week, ANI Pharmaceuticals had 10 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 11 mentions for ANI Pharmaceuticals and 1 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.82 beat ANI Pharmaceuticals' score of 0.45 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
ANI Pharmaceuticals	Neutral
Phathom Pharmaceuticals	Very Positive

ANI Pharmaceuticals currently has a consensus price target of $100.00, indicating a potential upside of 39.98%. Phathom Pharmaceuticals has a consensus price target of $20.11, indicating a potential upside of 231.87%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43
Phathom Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

ANI Pharmaceuticals has a net margin of 11.22% compared to Phathom Pharmaceuticals' net margin of -30.19%. ANI Pharmaceuticals' return on equity of 28.34% beat Phathom Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.22%	28.34%	11.18%
Phathom Pharmaceuticals	-30.19%	N/A	-13.38%

ANI Pharmaceuticals has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Phathom Pharmaceuticals beats ANI Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Phathom Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHAT vs. The Competition

Export

Metric	Phathom Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$506.45M	$13.77B	$7.84B	$12.19B
Dividend Yield	N/A	2.56%	2.46%	4.53%
P/E Ratio	-5.88	29.40	34.71	28.44
Price / Sales	2.81	7.34	8.66	5.84
Price / Cash	N/A	15.74	21.93	22.49
Price / Book	-1.42	4.93	4.35	3.76
Net Income	-$221.25M	$2.88B	$3.51B	$390.55M
7 Day Performance	15.43%	-0.21%	-1.49%	-0.33%
1 Month Performance	-18.11%	-3.25%	-2.55%	-4.82%
1 Year Performance	-58.38%	-6.14%	0.92%	-5.83%

Phathom Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHAT Phathom Pharmaceuticals	3.8099 of 5 stars	$6.06 -2.7%	$20.11 +231.9%	-59.2%	$506.45M	$175.11M	N/A	371	Positive News
XERS Xeris Biopharma	2.0653 of 5 stars	$10.17 -5.0%	$13.20 +29.8%	+129.5%	$1.94B	$291.85M	N/A	435	Analyst Forecast Analyst Revision
TRVI Trevi Therapeutics	2.2331 of 5 stars	$13.63 +0.5%	$27.08 +98.7%	+19.1%	$1.93B	N/A	N/A	34	Earnings Report Analyst Revision
MLYS Mineralys Therapeutics	3.0535 of 5 stars	$15.55 -14.5%	$45.50 +192.6%	-65.4%	$1.89B	N/A	N/A	76	High Trading Volume
URGN Urogen Pharma	3.6944 of 5 stars	$34.36 +5.0%	$52.38 +52.4%	+9.4%	$1.65B	$109.79M	N/A	291

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHAT) was last updated on 11/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phathom Pharmaceuticals (PHAT) Competitors

PHAT vs. XERS, TRVI, MLYS, URGN, and ANIP

How does Phathom Pharmaceuticals compare to Xeris Biopharma?

Summary

How does Phathom Pharmaceuticals compare to Trevi Therapeutics?

Summary

How does Phathom Pharmaceuticals compare to Mineralys Therapeutics?

Summary

How does Phathom Pharmaceuticals compare to Urogen Pharma?

Summary

How does Phathom Pharmaceuticals compare to ANI Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT vs. The Competition

Phathom Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phathom Pharmaceuticals (PHAT) Competitors

PHAT vs. XERS, TRVI, MLYS, URGN, and ANIP

How does Phathom Pharmaceuticals compare to Xeris Biopharma?

Do insiders and institutionals have more ownership in PHAT or XERS?

Does the media favor PHAT or XERS?

Which has more volatility & risk, PHAT or XERS?

Is PHAT or XERS more profitable?

Do analysts recommend PHAT or XERS?

Which has higher earnings & valuation, PHAT or XERS?

Summary

How does Phathom Pharmaceuticals compare to Trevi Therapeutics?

Do institutionals & insiders have more ownership in TRVI or PHAT?

Does the media refer more to TRVI or PHAT?

Which has more risk & volatility, TRVI or PHAT?

Is TRVI or PHAT more profitable?

Do analysts rate TRVI or PHAT?

Which has stronger valuation and earnings, TRVI or PHAT?

Summary

How does Phathom Pharmaceuticals compare to Mineralys Therapeutics?

Do insiders and institutionals hold more shares of PHAT or MLYS?

Which has stronger earnings and valuation, PHAT or MLYS?

Do analysts rate PHAT or MLYS?

Does the media favor PHAT or MLYS?

Which has more volatility and risk, PHAT or MLYS?

Is PHAT or MLYS more profitable?

Summary

How does Phathom Pharmaceuticals compare to Urogen Pharma?

Do analysts prefer PHAT or URGN?

Which has more volatility and risk, PHAT or URGN?

Do insiders & institutionals believe in PHAT or URGN?

Does the media prefer PHAT or URGN?

Is PHAT or URGN more profitable?

Which has better earnings & valuation, PHAT or URGN?

Summary

How does Phathom Pharmaceuticals compare to ANI Pharmaceuticals?

Which has preferable valuation and earnings, ANIP or PHAT?

Does the media favor ANIP or PHAT?

Do analysts rate ANIP or PHAT?

Is ANIP or PHAT more profitable?

Which has more risk and volatility, ANIP or PHAT?

Do insiders and institutionals have more ownership in ANIP or PHAT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT vs. The Competition

Phathom Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools